Treatment of Tricuspid Valve Regurgitation: The Future Is Now

Affiliations

¹ Medizinische Klinik und Poliklinik I, Echocardiographic Core Laboratory, Klinikum der Universität München, Ludwig-Maximilians-University Munich, Munich, Germany. Electronic address: nabauer@med.lmu.de.
² Medizinische Klinik und Poliklinik I, Echocardiographic Core Laboratory, Klinikum der Universität München, Ludwig-Maximilians-University Munich, Munich, Germany; Deutsches Zentrum für Herz-Kreislaufforschung, Berlin, Germany.

Free article

Editorial

Michael Nabauer et al. JACC Cardiovasc Interv. 2021.

Free article

. 2021 Jan 11;14(1):51-53.

doi: 10.1016/j.jcin.2020.11.009.

¹ Medizinische Klinik und Poliklinik I, Echocardiographic Core Laboratory, Klinikum der Universität München, Ludwig-Maximilians-University Munich, Munich, Germany. Electronic address: nabauer@med.lmu.de.
² Medizinische Klinik und Poliklinik I, Echocardiographic Core Laboratory, Klinikum der Universität München, Ludwig-Maximilians-University Munich, Munich, Germany; Deutsches Zentrum für Herz-Kreislaufforschung, Berlin, Germany.

No abstract available

Keywords: Cardioband; heart failure; tricuspid regurgitation; valve repair; valve replacement.

Conflict of interest statement

Author Disclosures Drs. Nabauer and Orban have received speaker fees from Abbott Vascular and Edwards Lifesciences.

Early Feasibility Study of Cardioband Tricuspid System for Functional Tricuspid Regurgitation: 30-Day Outcomes.
Davidson CJ, Lim DS, Smith RL, Kodali SK, Kipperman RM, Eleid MF, Reisman M, Whisenant B, Puthumana J, Abramson S, Fowler D, Grayburn P, Hahn RT, Koulogiannis K, Pislaru SV, Zwink T, Minder M, Dahou A, Deo SH, Vandrangi P, Deuschl F, Feldman TE, Gray WA; Cardioband TR EFS Investigators. Davidson CJ, et al. JACC Cardiovasc Interv. 2021 Jan 11;14(1):41-50. doi: 10.1016/j.jcin.2020.10.017. JACC Cardiovasc Interv. 2021. PMID: 33413863